Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-006610
Filing Date
2017-08-14
Accepted
2017-08-14 09:15:04
Documents
69
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20170630x10q.htm 10-Q 1250159
2 EX-10.1 gemp-20170630ex101906a76.htm EX-10.1 89278
3 EX-10.2 gemp-20170630ex1020664a4.htm EX-10.2 25241
4 EX-31.1 gemp-20170630ex3110af395.htm EX-31.1 17574
5 EX-31.2 gemp-20170630ex312930e6a.htm EX-31.2 17664
6 EX-32.1 gemp-20170630ex321fd4bfc.htm EX-32.1 12026
  Complete submission text file 0001558370-17-006610.txt   4990677

Data Files

Seq Description Document Type Size
7 EX-101.INS gemp-20170630.xml EX-101.INS 778396
8 EX-101.SCH gemp-20170630.xsd EX-101.SCH 49275
9 EX-101.CAL gemp-20170630_cal.xml EX-101.CAL 27486
10 EX-101.DEF gemp-20170630_def.xml EX-101.DEF 193577
11 EX-101.LAB gemp-20170630_lab.xml EX-101.LAB 418648
12 EX-101.PRE gemp-20170630_pre.xml EX-101.PRE 336280
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 171027586
SIC: 2834 Pharmaceutical Preparations